Status: Recruiting
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
The overarching goal of this study is to determine if baricitinib, as compared to placebo, will improve neurocognitive function, along with measures of physical function, quality of life, post-exertional malaise, effect of breathlessness on daily activities, post-COVID-19 symptom burden, and biomarkers of inflammation and viral measures, in participants with Long COVID.
Participants needed: 550
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Wes ElyUpdated: May 11, 2026Locations: 17
Eligibility criteria
Evidence of personally signed and dated informed consent document indicating tha... [+5]
Qualifying Long COVID symptoms cannot be explained by an infection-associated ch... [+35]